Align Technology, Inc. - Common Stock (ALGN)
Healthcare › Orthopedic, Prosthetic & Surgical Appliances & Supplies
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 120% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 9.3% — below-average profitability
Align Technology, Inc. - Common Stock (ALGN) is a Healthcare company operating in Orthopedic, Prosthetic & Surgical Appliances & Supplies, listed on the NASDAQ , with a market capitalisation of $13.2 billion . Key value metrics: P/E ratio 34.1, P/B ratio 3.18, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Align Technology, Inc. - Common Stock — Fundamental Analysis Summary
Align Technology, Inc. - Common Stock (ALGN) is currently trading 120% above its Graham Number of $83.97, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 34.1x.
On financial health, ALGN shows a moderate Piotroski F-Score of 5/9, and modest return on equity of 9.3% (sector average: -20.6%), and manageable leverage with a debt-to-equity ratio of 0.54.
StockPik's composite Value Score for ALGN is 46/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ALGN reports a high gross margin of 68.6% (sector average: 39.4%) and a solid operating margin of 13.2%.
ALGN shows revenue growing at 1% year-over-year, with earnings declining at 3%.